The GRID-HAMD: standardization of the Hamilton Depression Rating Scale

Williams, Janet B. W.; Kobak, Kenneth A.; Bech, Per; Engelhardt, Nina; Evans, Ken; Lipsitz, Joshua D.; Olin, Jason T.; Pearson, Jay D.; Kalali, Amir H

doi:10.1097/yic.0b013e3282f948f5

Cited by 246 publications

(219 citation statements)

References 23 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…7. Within a month of the start of the next MBCT-TS group a current GRID-Hamilton Depression Rating Scale (GRID-HAMD) 49 score was obtained for each participant so that randomisation could occur.…”

Section: Recruitment Proceduresmentioning

confidence: 99%

“…Depression-free days were calculated using the SCID interview and residual depressive symptoms were assessed with the observer-rated interviewer-administered 17-item GRID-HAMD 49 and a well-established self-report measure, the Beck Depression Inventory, second edition (BDI-II). 55 Psychiatric comorbidity was assessed with the full SCID, 47 medical comorbidities were assessed at baseline, 12 and 24 months using the MSCL 56 and health-related quality of life status was assessed using the European Quality of Life-5 Dimensions three-level version (EQ-5D-3L) 57,58 and the WHO Quality of Life-BREF (WHOQOL-BREF).…”

Section: Secondary Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study)

Kuyken

Hayes

Barrett

et al. 2015

Health Technol Assess

106

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 08/56/01. The contractual start date was in January 2010. The draft report began editorial review in October 2014 and was accepted for publication in February 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by ...

show abstract

Section: Recruitment Proceduresmentioning

confidence: 99%

Section: Secondary Outcomesmentioning

confidence: 99%

The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study)

Kuyken

Hayes

Barrett

et al. 2015

Health Technol Assess

106

View full text Add to dashboard Cite

show abstract

“…It is an instrument for a semistructured interview based on DSM-VI criteria and it must be performed by a trained professional (22). The HRSD characterizes the symptoms of cognitive and physical signs of depression, depressed mood, and signs and symptoms of anxiety.…”

Section: Hamilton Depression Rating Scale (Hrsd)mentioning

confidence: 99%

The Effect of Naltrexone on Memory Deficit Followed by Electroconvulsive Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial

Motazedian

Noorbakhsh

Shams

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Electroconvulsive therapy (ECT) is famously known as a treatment for depression; however, memory impairments have always been a point of concern. The use of opioid antagonists may protect against the development of memory deficits after ECT. The current study aimed at assessing the effect of Naltrexone in diminishing memory impairments. Methods: This randomized, double-blinded, placebo-controlled clinical trial took place at Imam Hossein hospital of Tehran/Iran. Patients diagnosed with MDD, were assigned to either Naltrexone or placebo and received 6 sessions of ECT within 2 weeks. Wechsler Memory Scale was performed the day before the first session of ECT, as well as 2 weeks, 1 and 3 months after finishing the 6th session. The Hamilton depression rating scale was performed 2 times to examine the possible interference caused by depression or to relapse as a confounding variable. Results: Patients receiving Naltrexone and placebo showed no significant difference in WMS scores. However, after further assessment, changes of WMS scores in every round were compared; the results showed that after 2 weeks from baseline, the amount of the reduction of total WMS scores from baseline was significantly lower in the Naltrexone group (P = 0.04). Conclusions: This study suggests that Naltrexone as compared to placebo has no advantageous effect on attenuating memory deficits in the long term. It is a smaller degree of memory decline that makes Naltrexone superior to placebo.

show abstract

“…Background factors, personality, and childhood adversity and life events were assessed between recruitment and randomisation, using the NewMood background questionnaire, 75 given to patients to complete and return at the next visit. This questionnaire includes the Big Five Inventory 44-item personality questionnaire, 76 Depression severity was determined using the HDRS17, rated using the GRID Hamilton Depression Rating Scale (GRID-HAMD) for improved reliability, 81 and the MADRS. 74 Randomisation visit (week 0)…”

Section: Screening Visit (Week -2)mentioning

confidence: 99%

Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study)

et al. 2015

View full text Add to dashboard Cite

BackgroundDepressed patients who do not respond to second-line antidepressant drugs are characterised as suffering from treatment-refractory depression (TRD). Chronic psychosocial stress hypothalamic–pituitary–adrenal (HPA) axis dysfunction is associated with attenuated responses to antidepressants. Corticosteroid co-administration reduces the increase in forebrain 5-hydroxytryptamine with selective serotonin reuptake inhibitors, whereas antiglucocorticoids have the opposite effect. A Cochrane review suggesting that antiglucocorticoid augmentation of antidepressants may be effective in treating TRD included a pilot study of the cortisol synthesis inhibitor, metyrapone. TheAntiglucocorticoid augmentation of antiDepressants inDepression (ADD Study) was a multicentre randomised placebo-controlled trial of metyrapone augmentation of serotonergic antidepressants in patients with TRD.ObjectiveTo determine the efficacy and safety of augmentation of standard serotonergic antidepressants with metyrapone 500 mg twice a day for 3 weeks in patients with TRD.MethodsA total of 165 patients with moderate to severe TRD aged 18–65 years were randomised to metyrapone 500 mg twice daily or placebo for 3 weeks, in addition to ongoing serotonergic antidepressants. The primary outcome was improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) score 5 weeks after randomisation estimated using analysis of covariance. Secondary outcomes included the degree of persistence of treatment effect for up to 6 months, and also safety and tolerability of metyrapone. ADD included substudies investigating the potential mechanism of action of metyrapone, and utilised a comparator group of healthy participants.ResultsThe estimated mean difference for each of our study outcomes between randomised groups, 5 weeks post randomisation (allowing for variation between centres and whether or not patients originate from primary or secondary care) was MADRS –0.51 [95% confidence interval (CI) –3.48 to 2.46]; Beck Depression Inventory (BDI) –2.65 (95% CI –6.41 to 1.10); Clinical Anxiety Scale 0.46 (95% CI –1.20 to 2.12); State–Trait Anxiety Inventory 1.2 (95% CI –0.6 to 3.0); European Quality of Life-5 Dimensions 0.015 (95% CI –0.069 to 0.099); EuroQol visual analogue scale 5.6 (95% CI –0.7 to 12.0); and Young Mania Rating Scale –0.04 (95% CI –0.52 to 0.45). The differences were not statistically significant and were small in relation to the change from baseline in both groups that was observed immediately after completion of therapy. Endocrinological data required for compliance assessment are not yet available. HPA function, similar in patients and control subjects, was not associated with differing clinical responses. Neuropsychological impairments were found, along with changes in brain structure and function, but no effect of metyrapone was seen on these measures.DiscussionThe inclusion criteria led to the sample being broadly representative of patients with TRD, within the UK NHS, with high anxiety and BDI scores. Metyrapone augmentation of antidepressants is not efficacious for outpatients with TRD who are moderately depressed. There was no obvious benefit associated with the use of metyrapone, either on the primary outcome or over the period of follow-up, and this negative result extended to other secondary outcomes. Metyrapone was well tolerated. There were no serious adverse events attributable to it and adverse events were as common with the placebo. HPA axis function was not associated with differing clinical or neuropsychological outcomes.ConclusionsThe results of the study suggest that although metyrapone augmentation was well tolerated, it is ineffective in the treatment of refractory depression. This finding is contrary to a previous proof of principle study in more acutely unwell patients. Future research should consider whether or not antiglucocorticoid treatments, such as metyrapone, should be targeted at patients with confirmed hypercortisolaemia.Trial registrationCurrent Controlled Trials ISRCTN45338259.Funding detailsThis study was funded by the National Institute for Health Research Efficacy and Mechanism Evaluation (EME) programme, a MRC and NIHR partnership.

show abstract

The GRID-HAMD: standardization of the Hamilton Depression Rating Scale

Cited by 246 publications

References 23 publications

The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study)

The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study)

The Effect of Naltrexone on Memory Deficit Followed by Electroconvulsive Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial

Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study)

Contact Info

Product

Resources

About